Biocytogen’s Post

Topo1i-based ADC and PARPi combination therapy is expected to demonstrate significant synergy. Recent studies have shown that sequential administration is better tolerated than concurrent administration. PARG removes PAR chains added by PARP once DNA repair is completed. This removal of PAR chains halts the recruitment of DNA repair proteins and prevents excessive PAR accumulation. These PARG actions are crucial for maintaining normal cell function; therefore, combining Topo1i-based ADC and PARG inhibitors could be a viable strategy. Additionally, while no drugs targeting B7-H3 and PTK7 have been approved, considerable information has been gathered from various clinical experiences.

💥💥💥 Synthetic Approaches and Clinical Application of Representative Small-Molecule Inhibitors of Cyclin-Dependent Kinase for Cancer Therapy. The regulation of the cancer cell cycle heavily relies on cyclin-dependent kinases (CDKs). Targeting CDKs has been identified as a promising approach for effective cancer therapy. In recent years, there has been significant attention paid towards developing small-molecule CDK inhibitors in the field of drug discovery. Notably, five such inhibitors have already received regulatory approval for the treatment of different cancers, including breast tumors, lung malignancies, and hematological malignancies. This review provides an overview of the synthetic routes used to produce 17 representative small-molecule CDK inhibitors that have obtained regulatory approval or are currently being evaluated through clinical trials. It also discusses their clinical applications for treating CDK-related diseases and explores the challenges and limitations associated with their use in a clinical setting, which will stimulate the further development of novel CDK inhibitors. By integrating therapeutic applications, synthetic methodologies, and mechanisms of action observed in various clinical trials involving these CDK inhibitors, this review facilitates a comprehensive understanding of the versatile roles and therapeutic potential offered by interventions targeting CDKs. #drugdiscovery #smallmolecules #inhibitors #research #biotech #medicinalchemistry #drugspharmaceuticals #hitcompound #bioactivity #pharmaceuticalsciences #treatment #diseasetreatment #biotech #research #targets #leadgeneration #Cancertherapy #cancertreatment

Exciting developments in the field of Antibody Drug Conjugates (ADCs) are shaping the landscape of targeted cancer therapies. With a growing market size driven by increasing investments and deals, ADCs offer promising prospects for precision medicine. The process involves attaching potent cytotoxic drugs to monoclonal antibodies, enabling targeted delivery to cancer cells while minimizing systemic toxicity. Looking ahead, advancements in ADC technology hold immense potential for enhancing efficacy, expanding indications, and improving patient outcomes in the fight against cancer. Innovations in ADC research and development continue to drive progress towards more effective and personalized cancer treatments. As investments pour into this burgeoning field and collaborations flourish, we anticipate further breakthroughs in ADC technology, paving the way for transformative therapies and improved standards of care for cancer patients worldwide. #ADC #Antibodydrugconjugate #ResearchAndDevelopment #Collaboration #TransformativeTherapies #PatientOutcomes

💥💥💥 Synthetic Approaches and Clinical Application of Representative Small-Molecule Inhibitors of Cyclin-Dependent Kinase for Cancer Therapy. The regulation of the cancer cell cycle heavily relies on cyclin-dependent kinases (CDKs). Targeting CDKs has been identified as a promising approach for effective cancer therapy. In recent years, there has been significant attention paid towards developing small-molecule CDK inhibitors in the field of drug discovery. Notably, five such inhibitors have already received regulatory approval for the treatment of different cancers, including breast tumors, lung malignancies, and hematological malignancies. This review provides an overview of the synthetic routes used to produce 17 representative small-molecule CDK inhibitors that have obtained regulatory approval or are currently being evaluated through clinical trials. It also discusses their clinical applications for treating CDK-related diseases and explores the challenges and limitations associated with their use in a clinical setting, which will stimulate the further development of novel CDK inhibitors. By integrating therapeutic applications, synthetic methodologies, and mechanisms of action observed in various clinical trials involving these CDK inhibitors, this review facilitates a comprehensive understanding of the versatile roles and therapeutic potential offered by interventions targeting CDKs. #drugdiscovery #smallmolecules  #inhibitors #research #biotech #medicinalchemistry #drugspharmaceuticals #hitcompound #bioactivity #pharmaceuticalsciences #treatment #diseasetreatment #biotech #research #targets #leadgeneration #cancer #cancertherapy #Cancertarget #cancertreatment

Welcome to Wednesday Words, where each Wednesday morning I will give you a definition of one word used in biotechnology or biopharma! CAR T-cells (Chimeric Antigen Receptor T-cells) represent a groundbreaking advancement in cancer immunotherapy. These genetically engineered T-cells are designed to recognize and attack cancer cells with precision. By modifying a patient’s own T-cells to express a receptor specific to cancer cells, CAR T-cell therapy provides a personalized and powerful treatment option. This innovative approach has shown remarkable success in treating certain types of blood cancers, offering new hope to patients with previously incurable conditions. As research progresses, CAR T-cell therapy holds promise for expanding its application to other cancer types and revolutionizing cancer treatment. If you want to learn more, check out: https://lnkd.in/gdjz8MzY #wednesdaywords #biotechnology #biopharma #CARTCells #CancerTreatment #Immunotherapy #MedicalScience #Healthcare #GeneticEngineering #CancerResearch #Biotechnology #Pharmaceuticals #HealthTech #PersonalizedMedicine #Oncology #InnovativeTherapies #ScientificResearch #CancerImmunotherapy

At MonTa Biosciences, we’re thrilled to announce the successful completion of a new dose level in the Phase I dose-escalation oncology study of our immunotherapy drug, MBS8. This achievement wouldn’t have been possible without the dedication and expertise of our committed investigators in Denmark, Belgium, and Spain. This latest milestone allows us to advance to even higher dose levels in the next patient cohort, highlighting the encouraging safety profile of MBS8. By doing so, we are paving the way toward more effective treatment options with greater potential for anti-tumor activity and improved patient outcomes. Given the challenge in the field of achieving a robust therapeutic index with systemic innate immunotherapy, we are particularly proud that MBS8, designed for an enhanced therapeutic index, shows tolerability more than 6 times greater than TLR7 agonists previously tested in clinical trials. With MBS8 showing an improved therapeutic activity versus benchmark TLR7 agonists in preclinical studies, we are looking at exciting times ahead as we continue to explore the potential of MBS8 in transforming cancer care! 💪🏼✨ #CancerResearch #Immunotherapy #ClinicalTrials #Oncology #MBS8 #MonTaBiosciences #InnovationInMedicine #LifeSciences #Biotech #Collaboration  

Exciting partnership in oncology! 🔬🚀 Boehringer Ingelheim and Circle Pharma are teaming up, potentially creating a seismic shift in cancer treatment. This partnership, worth up to $607 million, highlights how targeted partnerships can accelerate the progress towards effective and innovative cancer therapies. Circle Pharma is renowned for its work in macrocyclic peptides, a class of molecules capable of targeting challenging sites within cells. This alliance, fuelled by Boehringer Ingelheim's strategic focus on proteins driving tumor growth, could pave the way to groundbreaking advancements in oncology treatment. It's fascinating to see how Circle's approach of rational drug design and synthetic chemistry is aligning perfectly with Boehringer's goals. This step is particularly significant for the battle against cancer, as issues like toxicity and low selectivity have long plagued the development of cyclin-dependent kinase inhibitors. Circle's potential solution marks a hopeful turn in tackling these challenges. #Oncology #Biotech #Innovation #Partnership #Pharmaceuticals

Please check our new publication in Nature Communications displaying technology innovation at Predicine in collaboration with Dana Farber to address treatment selection, response monitoring, and resistance detection in GEA. A great summary is shown below. #MRD #methylation #liquidbiopsy

🎯 Targeting a Key Player in Cancer: AKT, known for its role in cell growth and survival, is a prime target in oncology due to its involvement in tumor growth and drug resistance. Despite the challenges, advancements in AKT inhibitor development show promise. 💡 Spotlight on Progress: Leading compounds ipatasertib and capivasertib are showing potential in HR+ breast cancer, triple-negative breast cancer, and prostate cancer. Novartis's afuresertib and uprosertib, inherited from GSK, have shown encouraging results in early-phase trials across several cancers. 🔬 Comprehensive Screening: Kyinno Biotechnology has developed a specialized cell model for comprehensive screening of AKT inhibitors, catering to various AKT mutations, thus advancing the precision and efficacy of cancer therapies. 🤝 Connect with us to explore how our AKT inhibitor screening can advance your research and development efforts. #CancerResearch #Oncology #DrugDevelopment #Pharmaceuticals #Innovation #AKTInhibitors #KyinnoBIotechnology

We are delighted to announce our collaboration with Agios Pharmaceuticals, a Cambridge-based renowned leader in cancer metabolism therapies. Together, we have crafted a unique illustration that not only graces the cover of Cancer Cell but also represents a significant step forward in our understanding of cancer metabolism therapies. 🔬 This cover represents Agios's pioneering work on the anti-cancer effects of MAT2A inhibitors. MAT2A acts like a power source, fueling specific metabolic processes in cancer cells. By modulating the activity of PRMT5, akin to a light bulb, these inhibitors effectively slow down cancer growth in cells missing the MTAP gene. 🎨 Our illustration is a testament to the innovative spirit that drives cancer research. It aims to visualize the complex interaction between MAT2A inhibitors and cancer cells in a way that's both engaging and scientifically insightful. This fusion of art and science illustrates the hope and innovation that propel cancer research forward. 💡 We hope this piece inspires you as much hope and curiosity as it does in us. Let's continue the conversation about the revolutionary advances in cancer treatment. #CancerResearch #Pharmaceuticals #Biotech #ScienceArt #AgiosPharma #CancerCell #Illustration #ScienceCommunication #InnovationInMedicine #MAT2A #PRMT5 #CancerTherapy